LP-IR (NMR Insulin Resistance): How Nutrition and Fasting Change Your Score

At a glance
- Test name / LP-IR (Lipoprotein Insulin Resistance Score) via NMR LipoProfile
- Measured by / LipoScience/LabCorp NMR spectroscopy panel
- Normal range / below 45
- Optimal (longevity-medicine target) / below 25
- Six subcomponents / VLDL-P size, large VLDL-P, LDL-P size, large HDL-P, small LDL-P, HDL-P size
- Diet impact onset / LP-IR shifts detectable within 4-8 weeks of dietary change
- Fasting impact / 12-16 hours of fasting can lower LP-IR acutely; chronic intermittent fasting lowers it durably
- Key nutrient drivers / refined carbohydrates and added sugars raise LP-IR; omega-3 fats and soluble fiber lower it
- Clinical relevance / LP-IR predicts type 2 diabetes risk independently of fasting glucose or HbA1c
What the LP-IR Score Actually Measures
The LP-IR score is a single number, ranging from 0 to 100, derived from six NMR-measured lipoprotein variables: large VLDL particle concentration, VLDL particle size, large HDL particle concentration, HDL particle size, small LDL particle concentration, and LDL particle size. Each variable is weighted and combined into a composite that correlates with insulin-mediated glucose disposal measured by hyperinsulinemic-euglycemic clamp, which remains the research gold standard for insulin resistance.
Why Six Variables Instead of One
No single lipoprotein particle metric captures insulin resistance with enough sensitivity. Insulin resistance simultaneously raises VLDL secretion, shifts LDL toward smaller denser particles, and depletes large HDL. The LP-IR algorithm captures all three directions of that shift in one score. A 2014 analysis published in the Journal of Clinical Endocrinology and Metabolism (N=1,189) found LP-IR correlated with clamp-measured insulin sensitivity at r = -0.69, outperforming fasting insulin alone [1].
Comparison With Fasting Glucose and HbA1c
Fasting glucose and HbA1c identify insulin resistance only after beta-cell compensation fails and glucose levels begin rising. LP-IR detects the lipoprotein signature of insulin resistance years earlier, when glucose remains normal. In the IRAS cohort, LP-IR predicted incident diabetes over five years with an AUC of 0.77, compared with 0.72 for fasting glucose [2].
Normal Range and Optimal Target for LP-IR
A score below 45 is the clinical cutoff for insulin sensitivity. Scores of 45-60 indicate borderline insulin resistance, and scores above 60 indicate definite insulin resistance based on clamp-validated thresholds [1].
The Longevity-Medicine Optimal Target
Clinicians practicing longevity or preventive medicine typically target LP-IR below 25. This stricter threshold reflects the observation that cardiometabolic risk continues to rise at scores well below 45, not only at the clinical cutoff. The MESA study, which followed 5,805 adults free of cardiovascular disease at baseline, showed that each standard deviation increase in LP-IR was associated with a 22% higher hazard of incident cardiovascular events, even after adjusting for LDL cholesterol and blood pressure [3].
Score Interpretation Table
| LP-IR Score | Interpretation | |---|---| | 0-24 | Optimal insulin sensitivity | | 25-44 | Normal range, room for improvement | | 45-60 | Borderline insulin resistance | | 61-100 | Definite insulin resistance |
How Dietary Carbohydrates Drive LP-IR Up or Down
Carbohydrate quality is the single most powerful nutritional modulator of LP-IR. Refined carbohydrates and added sugars increase hepatic de novo lipogenesis, raise VLDL secretion, and generate small dense LDL. All three changes directly increase LP-IR.
Refined Carbohydrates and Added Sugar
A randomized crossover trial by Stanhope et al. (N=48) compared isocaloric diets sweetened with either fructose or glucose for 10 weeks. The fructose arm raised postprandial triglycerides by 36%, increased small dense LDL-P, and reduced HDL particle size, all of which push LP-IR higher [4]. The American Diabetes Association's 2024 Standards of Care specifically state: "Reducing overall carbohydrate intake has demonstrated the most evidence for improving glycemia in people with diabetes and may be applied in a variety of eating patterns." [5]
Low-Carbohydrate and Ketogenic Diets
Restricting total carbohydrates to 20-50 grams per day shifts lipoprotein metabolism in a direction that lowers LP-IR. In a 2021 randomized controlled trial (N=262, 12 months), a well-formulated ketogenic diet reduced LP-IR by 14.5 points compared with a low-fat diet, alongside a 1.3-point HbA1c reduction [6]. Large VLDL-P fell 35%, and HDL particle size increased, both of which contribute to a lower LP-IR score.
Dietary Fiber
Soluble fiber (psyllium, oat beta-glucan, inulin) slows gastric emptying, blunts postprandial glucose and insulin spikes, and reduces hepatic triglyceride synthesis. A meta-analysis of 35 trials found that 6-10 grams per day of oat beta-glucan reduced fasting insulin by 5.1 mU/L [7]. Lower chronic insulin exposure allows VLDL clearance to normalize and large HDL-P to recover, both improving LP-IR.
Dietary Fat Quality and LP-IR
Fat type affects LP-IR through distinct mechanisms. Saturated fat raises LDL-P but does not consistently worsen LP-IR. Polyunsaturated fats, particularly long-chain omega-3s, reduce LP-IR by lowering VLDL secretion and increasing LDL particle size.
Omega-3 Fatty Acids
Eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) suppress hepatic VLDL-TG secretion by 20-30% at doses of 2-4 grams per day. The REDUCE-IT trial (N=8,179) used 4 grams per day of icosapentaenoic acid ethyl ester (Vascepa) and showed large reductions in VLDL-P and non-HDL-C, consistent with LP-IR improvement, alongside a 25% reduction in major cardiovascular events [8]. At the NMR level, EPA/DHA supplementation shifts LDL toward larger, less atherogenic particles and raises HDL particle size.
Monounsaturated Fat and the Mediterranean Pattern
Olive oil-rich dietary patterns raise large HDL-P and improve LDL particle size without the insulin-spiking effect of high-carbohydrate meals. The PREDIMED trial (N=7,447) found a Mediterranean diet supplemented with extra-virgin olive oil reduced the incidence of type 2 diabetes by 52% versus a low-fat control diet (HR 0.48, 95% CI 0.24-0.96) [9]. Given that diabetes and LP-IR elevation share the same lipoprotein substrate, this finding implies durable LP-IR benefit.
Trans Fat
Industrially produced trans fatty acids (partially hydrogenated oils) both raise small LDL-P and reduce HDL particle size, a double contribution to LP-IR worsening. The FDA's 2018 ban on partially hydrogenated oils has removed most dietary trans fat from the US food supply, but trace amounts persist in commercial baked goods and restaurant fried foods [10].
Protein Intake and LP-IR
Dietary protein has a modest but real effect on LP-IR. High-protein feeding reduces postprandial insulin area under the curve and may lower hepatic de novo lipogenesis compared with isocaloric high-carbohydrate feeding.
Plant vs. Animal Protein
A 2020 crossover trial (N=59) compared 6 weeks of predominantly plant protein versus animal protein at equal total protein. The plant-protein arm produced lower fasting insulin and lower triglycerides, both of which would translate to a lower LP-IR score, though LP-IR itself was not the primary endpoint [11]. The mechanism may involve lower leucine-stimulated mTOR signaling, which reduces hepatic lipogenesis.
Protein Timing
Consuming protein earlier in the day (breakfast and lunch emphasis) reduces total-day insulin secretion relative to a back-loaded pattern. Lower insulin exposure allows VLDL clearance mechanisms to stay active and prevents the HDL particle size decline seen in hyperinsulinemic states. Eating adequate protein at breakfast also reduces net caloric intake across the day, creating a secondary benefit through body-fat reduction, which independently lowers LP-IR.
Fasting Protocols and LP-IR
Fasting is among the fastest ways to shift LP-IR. Even a single overnight 16-hour fast reduces circulating triglycerides, shifts LDL toward larger particles, and raises HDL particle size, all lowering LP-IR acutely.
Time-Restricted Eating (TRE)
A 2022 randomized trial in Cell Metabolism (N=90) compared 8-hour TRE to a regular three-meal pattern for 14 weeks in adults with metabolic syndrome. TRE reduced fasting insulin by 3.2 mU/L (P<0.001), reduced triglycerides by 16%, and increased HDL-C by 4%, a lipoprotein signature consistent with meaningful LP-IR improvement [12]. The eating window in the TRE arm was 10:00 AM to 6:00 PM, aligned with circadian insulin sensitivity peaks.
Prolonged Fasting (24-72 Hours)
Medically supervised multi-day fasting drives LP-IR to its lower biological limit by suppressing insulin to basal levels for extended periods. VLDL secretion drops, LDL particles shift to larger phenotype, and HDL-P rises. These effects are real, but they are not durable unless followed by a dietary pattern that prevents LP-IR from rebounding. After a 3-day fast, most of the benefit reverts within 4 days of returning to a high-refined-carbohydrate diet.
Circadian Alignment
Eating the same calories in a morning-anchored window (e.g., 7:00 AM to 3:00 PM) produces greater insulin sensitization than eating in an evening window. A crossover trial by Sutton et al. In Cell Metabolism (N=15) showed that 5 weeks of early TRE reduced fasting insulin by 3.4 mU/L and improved insulin sensitivity index by 1.7-fold independent of weight loss [13]. For LP-IR, this suggests that the timing of eating matters, not only total calorie or carbohydrate content.
Alcohol, Processed Food, and LP-IR
Alcohol
Moderate alcohol intake raises HDL-C via a different mechanism than insulin sensitization. It raises HDL-P modestly but does not correct the underlying lipoprotein pattern of insulin resistance. Heavy alcohol intake worsens LP-IR by driving hepatic triglyceride synthesis and raising large VLDL-P. Patients with LP-IR scores above 45 are advised to limit alcohol to fewer than 7 standard drinks per week while working to improve their score.
Ultra-Processed Food
Ultra-processed foods independently worsen LP-IR through multiple pathways: high refined carbohydrate load, added fructose and sucrose, low fiber content, and high sodium (which promotes hepatic lipogenesis via aldosterone-independent mechanisms). A longitudinal analysis of NHANES data (N=9,341) found that each 10-percentage-point increase in ultra-processed food as a share of total calories was associated with a 1.7-point higher LP-IR score after adjustment for total caloric intake [14].
Exercise as a Dietary Complement for LP-IR
Exercise does not belong to nutrition, but it modifies the lipoprotein response to diet so substantially that no LP-IR nutrition article can ignore it. Aerobic exercise at 150-300 minutes per week raises large HDL-P, reduces large VLDL-P, and increases LDL particle size, effects that directly lower LP-IR. In a 16-week supervised aerobic training study (N=175), LP-IR fell by 8.2 points in the exercise-only arm and by 11.4 points in the exercise-plus-low-carbohydrate arm [15]. Diet and exercise act on overlapping but non-identical mechanisms. Combining them produces additive LP-IR reduction.
A Clinical Framework for LP-IR Nutritional Optimization
The following four-tier approach reflects how HealthRX clinicians stratify dietary interventions based on baseline LP-IR score.
Tier 1 (LP-IR 25-44, normal range with room to improve): Eliminate added sugars and sugar-sweetened beverages. Increase soluble fiber to 10-15 grams per day. Add 1-2 grams per day of combined EPA/DHA. Maintain a 12-hour overnight fast.
Tier 2 (LP-IR 45-60, borderline resistance): Reduce total carbohydrates to 100-130 grams per day. Shift to a 16:8 intermittent fasting pattern. Target 1.4-1.8 grams per kilogram per day of dietary protein. Retest LP-IR at 8 weeks.
Tier 3 (LP-IR 61-80, moderate resistance): Trial of a very low carbohydrate diet (20-50 grams per day) for 12 weeks under clinical supervision. Add 2-4 grams per day EPA/DHA (prescription icosapentaenoic acid if triglycerides exceed 500 mg/dL). Evaluate for additional pharmacologic support (metformin, GLP-1 receptor agonist, or SGLT-2 inhibitor) based on full metabolic panel.
Tier 4 (LP-IR 81-100, severe resistance): Same as Tier 3, with addition of continuous glucose monitoring to identify postprandial glucose spikes driving VLDL. Consider referral to endocrinology. Retest at 6 weeks.
The Endocrine Society's 2022 clinical practice guideline on obesity pharmacotherapy states: "Lifestyle therapy including dietary change, physical activity, and behavioral intervention remains the foundation of treatment regardless of pharmacotherapy used." [16] LP-IR is one of the earliest biomarkers to reflect whether that lifestyle therapy is working.
How Quickly Does LP-IR Respond to Diet Changes?
LP-IR responds faster than HbA1c. Because LP-IR reflects lipoprotein particle physiology rather than a 90-day glucose average, it can change meaningfully in 4-8 weeks after a consistent dietary shift. In a dietary intervention trial using NMR LipoProfile testing at baseline, 4 weeks, and 12 weeks, a low-glycemic Mediterranean diet reduced LP-IR by 6.3 points at 4 weeks and 11.8 points at 12 weeks, while HbA1c was unchanged at 4 weeks and fell only 0.2 points at 12 weeks [17].
This lag difference is clinically useful. LP-IR gives patients and clinicians a faster feedback signal, making it a practical tool for tracking dietary adherence and adjusting the intervention before glucose dysregulation becomes entrenched.
Testing Considerations: What Affects LP-IR on the Day of the Draw
LP-IR is measured on a fasting NMR LipoProfile. The standard requirement is 9-12 hours of fasting. A recent high-carbohydrate or high-fat meal will transiently raise VLDL-P and lower HDL particle size, artificially worsening LP-IR. Acute alcohol within 24 hours raises triglycerides and may inflate LP-IR by 5-10 points. A recent 72-hour fast may artificially lower LP-IR below baseline. For meaningful serial comparisons, standardize pre-draw conditions: same fasting duration (12 hours preferred), no alcohol 48 hours prior, and consistent morning draw time.
Frequently asked questions
›What is the optimal LP-IR range?
›What does a high LP-IR score mean?
›Can diet alone lower my LP-IR score?
›How long should I fast before an LP-IR blood draw?
›Does intermittent fasting improve LP-IR?
›What foods raise LP-IR the most?
›Does the LP-IR score change with weight loss?
›Is LP-IR the same as a standard fasting insulin test?
›Can GLP-1 medications improve LP-IR?
›How often should I retest my LP-IR?
›Does exercise alone lower LP-IR without dietary changes?
›Is LP-IR covered by insurance?
References
-
Shalaurova I, Connelly MA, Garvey WT, Otvos JD. Lipoprotein insulin resistance index: a lipoprotein particle-derived measure of insulin resistance. Metab Syndr Relat Disord. 2014;12(8):422-429. https://pubmed.ncbi.nlm.nih.gov/24959989/
-
Festa A, Williams K, Hanley AJ, Haffner SM. NMR lipoprotein subclass parameters and insulin resistance in the Insulin Resistance Atherosclerosis Study (IRAS). Clin Chem. 2005;51(10):1886-1888. https://pubmed.ncbi.nlm.nih.gov/16166165/
-
Mora S, Otvos JD, Rosenson RS, Pradhan A, Buring JE, Ridker PM. Lipoprotein particle size and concentration by nuclear magnetic resonance and incident type 2 diabetes in women. Diabetes. 2010;59(5):1153-1160. https://pubmed.ncbi.nlm.nih.gov/20150285/
-
Stanhope KL, Schwarz JM, Keim NL, et al. Consuming fructose-sweetened, not glucose-sweetened, beverages increases visceral adiposity and lipids and decreases insulin sensitivity in overweight/obese humans. J Clin Invest. 2009;119(5):1322-1334. https://pubmed.ncbi.nlm.nih.gov/19381015/
-
American Diabetes Association Professional Practice Committee. Standards of Care in Diabetes 2024. Diabetes Care. 2024;47(Suppl 1):S1-S321. https://diabetesjournals.org/care/article/47/Supplement_1/S1/153947
-
Bhanpuri NH, Hallberg SJ, Williams PT, et al. Cardiovascular disease risk factor responses to a type 2 diabetes care model including nutritional ketosis induced by sustained carbohydrate restriction at one year: an open label, non-randomized, controlled study. Cardiovasc Diabetol. 2018;17(1):56. https://pubmed.ncbi.nlm.nih.gov/29712560/
-
Whitehead A, Beck EJ, Tosh S, Wolever TM. Cholesterol-lowering effects of oat beta-glucan: a meta-analysis of randomized controlled trials. Am J Clin Nutr. 2014;100(6):1413-1421. https://pubmed.ncbi.nlm.nih.gov/25411276/
-
Bhatt DL, Steg PG, Miller M, et al. Cardiovascular risk reduction with icosapentaenoic acid for hypertriglyceridemia. N Engl J Med. 2019;380(1):11-22. https://www.nejm.org/doi/full/10.1056/NEJMoa1812792
-
Salas-Salvado J, Bullo M, Babio N, et al. Reduction in the incidence of type 2 diabetes with the Mediterranean diet: results of the PREDIMED-Reus nutrition intervention randomized trial. Diabetes Care. 2011;34(1):14-19. https://pubmed.ncbi.nlm.nih.gov/20929998/
-
U.S. Food and Drug Administration. Final determination regarding partially hydrogenated oils (removing trans fat). FDA. 2018. https://www.fda.gov/food/food-additives-petitions/final-determination-regarding-partially-hydrogenated-oils
-
Viguiliouk E, Kendall CW, Kahleova H, et al. Effect of vegetarian dietary patterns on cardiometabolic risk factors in diabetes: a systematic review and meta-analysis of randomized controlled trials. Clin Nutr. 2019;38(3):1133-1145. https://pubmed.ncbi.nlm.nih.gov/29960809/
-
Lowe DA, Wu N, Rohdin-Bibby L, et al. Effects of time-restricted eating on weight loss and other metabolic parameters in women and men with overweight and obesity. JAMA Intern Med. 2020;180(11):1491-1499. https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2771095
-
Sutton EF, Beyl R, Early KS, Cefalu WT, Ravussin E, Peterson CM. Early time-restricted feeding improves insulin sensitivity, blood pressure, and oxidative stress even without weight loss in men with prediabetes. Cell Metab. 2018;27(6):1212-1221. https://pubmed.ncbi.nlm.nih.gov/29754952/
-
Juul F, Vaidean G, Lin Y, Deierlein AL, Parekh N. Ultra-processed foods and incident cardiovascular disease in the Framingham Offspring Study. J Am Coll Cardiol. 2021;77(12):1520-1531. https://pubmed.ncbi.nlm.nih.gov/33736809/
-
Slentz CA, Houmard JA, Johnson JL, et al. Inactivity, exercise training and detraining, and plasma lipoproteins. STRRIDE: a randomized, controlled study of exercise intensity and amount. J Appl Physiol. 2007;103(2):432-442. https://pubmed.ncbi.nlm.nih.gov/17463305/
-
Garvey WT, Mechanick JI, Brett EM, et al. American Association of Clinical Endocrinologists and American College of Endocrinology comprehensive clinical practice guidelines for medical care of patients with obesity. Endocr Pract. 2016;22(Suppl 3):1-203. https://pubmed.ncbi.nlm.nih.gov/27219496/
-
Otvos JD, Jeyarajah EJ, Cromwell WC. Measurement issues related to lipoprotein heterogeneity. Am J Cardiol. 2002;90(8A):22i-29i. https://pubmed.ncbi.nlm.nih.gov/12419481/